QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yang, M. Articles by Mascarenas, C. A Search for Related Content PubMed PubMed Citation Articles by Yang, M. Articles by Mascarenas, C. A

PSYCHIATRY

Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997–2002

Senior Scientist, QualityMetric Health Outcomes Solutions, Lincoln, RI

Jamie C Barner, PhD

Associate Professor, College of Pharmacy, The University of Texas at Austin, Austin, TX

Kenneth A Lawson, PhD

Associate Professor, College of Pharmacy, The University of Texas at Austin

Karen L Rascati, PhD

Professor, College of Pharmacy, The University of Texas at Austin

James P Wilson, PhD

Associate Professor, College of Pharmacy, The University of Texas at Austin

M Lynn Crismon, PharmD

Dean and Professor, College of Pharmacy, The University of Texas at Austin

Jason Worchel, MD

US Department of Veterans Affairs, Central Texas Veterans Health Care System, Temple, TX

Cynthia A Mascarenas, PharmD MS

US Department of Veterans Affairs, South Texas Veterans Health Care System, San Antonio, TX

Reprints: Dr. Yang, Outcomes Insight Consulting, QualityMetric Health Outcomes Solutions, 640 George Washington Hwy., Ste. 201, Lincoln, RI 02865, fax 401/334-8801, myang{at}QualityMetric.com

BACKGROUND: An antipsychotic utilization pattern has evolved substantially over the past 20 years or so due to the introduction of the second-generation antipsychotics (SGAs) and the increasing understanding of their adverse effect profile.

OBJECTIVE: To understand antipsychotic utilization trends (including monotherapy, antipsychotic switching, and combination therapy) and to investigate factors associated with antipsychotic index medication selection (SGAs vs first-generation antipsychotics [FGAs]) among Texas veterans.

METHODS: Data were taken from the Veterans Administration North Texas Health Care System (VANTHCS) and South Texas Veterans Health Care System (STVHCS) from January 1996 to December 2003. Adults with continuous enrollment (1 y before and after the index date) who had newly initiated antipsychotic therapy were included. Prescriptions were followed for up to 12 months. Descriptive analyses examined utilization trends; logistic regression evaluated factors associated with antipsychotic index medication selection.

RESULTS: A total of 8096 patients were included in the study (VANTHCS n = 4477; STVHCS n = 3619), with the majority being male (93.6%) and white (62.6%) and nearly half aged 55 years or older (44.1%). Between 1997 and 2002, antipsychotic prescriptions changed from primarily FGAs (1997: 71.7%; 1999: 25.2%; 2002: 5.7%) to SGAs. Over the 6-year time frame, risperidone (31.0%) and olanzapine (30.7%) were most commonly prescribed. The overall combination therapy slightly increased over time (4.3%), switching to another antipsychotic remained stable (14.2%), and antipsychotic monotherapy remained dominant (81.5%). Hispanic and black patients were less likely than white patients to be initiated on SGAs. Patients who were older, had hypertension, and were in STVHCS were less likely to start on SGAs. Patients with dyslipidemia, bipolar disorder, and treatment in recent years were more likely to start on SGAs.

CONCLUSIONS: SGAs have replaced FGAs as first-line medications for patients with mental disorders. Race, age, physical comorbidities (ie, dyslipidemia, hypertension), and treatment initiation year were important factors in index medication selection.

Key Words: antipsychotic, medication utilization, trends

Published Online, August 5, 2008. www.theannals.com, DOI 10.1345/aph.1L155